Clinical Trials Logo

Hematologic Neoplasms clinical trials

View clinical trials related to Hematologic Neoplasms.

Filter by:

NCT ID: NCT04603001 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia (AML)

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Start date: December 1, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who may have received standard therapy

NCT ID: NCT04557098 Active, not recruiting - Clinical trials for Hematological Malignancies

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

MajesTEC-1
Start date: September 17, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).

NCT ID: NCT04552288 Active, not recruiting - Solid Tumor Clinical Trials

Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

Start date: September 16, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out whether the study drug benralizumab is a safe treatment that can reduce the skin side effects caused by cancer treatment by reducing the level of eosinophils in your blood. Reducing the skin side effects of your cancer treatment may improve quality of life and allow participants to continue to receive their usual cancer treatment.

NCT ID: NCT04509765 Active, not recruiting - Clinical trials for Hematologic Malignancy

A Phase II Single-arm Study of Total Body Irradiation With Linac Based VMAT and IGRT

Start date: September 22, 2020
Phase: N/A
Study type: Interventional

Single institution study of safety of linac based VMAT TBI for myeloablative treatment in hematologic malignancies.

NCT ID: NCT04395222 Active, not recruiting - Clinical trials for Hematologic Malignancy

Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation

Start date: October 7, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety of reducing and ultimately eliminating anti-thymocyte globulin (ATG) from the haplo-cord transplant conditioning regimen and replacing it with tocilizumab, an IL-6 receptor monoclonal antibody, to improve immune reconstitution and reduce relapse while preserving low rates of graft failure and graft versus host disease (GVHD).

NCT ID: NCT04393363 Active, not recruiting - Clinical trials for Chemotherapy-induced Peripheral Neuropathy

Early Detection of Neuropathy and Cognitive Impairment Following Treatment for Haematological Malignancies

NOVIT1
Start date: August 14, 2020
Phase:
Study type: Observational

Chemotherapy-induced peripheral neuropathy (CIPN) is a common, but not well understood complication to treatment with chemotherapy. In this study the investigators will investigate a novel method for early detection of CIPN and compare it to other methods in patients treated for haematological cancers.

NCT ID: NCT04312841 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Start date: September 15, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well letermovir works for the prevention of cytomegalovirus reactivation in patients with hematological malignancies treated with alemtuzumab. Patients receiving treatment with alemtuzumab may experience cytomegalovirus reactivation. Letermovir may block cytomegalovirus replication and prevent infection.

NCT ID: NCT04280133 Active, not recruiting - Clinical trials for Hematologic Malignancy

CAR T-CELL Therapy Educational Video Trial

Start date: May 25, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to test a new educational video to help patients and doctors talk about CAR-T cell therapy, a treatment being used in cancer. - Educational video tool for patients receiving CAR-T cell therapy.

NCT ID: NCT04260698 Active, not recruiting - Clinical trials for Hematological Malignancies

Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

Start date: July 8, 2020
Phase: Phase 3
Study type: Interventional

Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.

NCT ID: NCT04205409 Active, not recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Start date: June 5, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well nivolumab works for the treatment of hematological malignancies that have come back (relapsed), does not respond (refractory), or is detectable after CAR T cell therapy. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.